#United States #INOVIO #Plymouth Meeting #INO-3107 #HPV-6

INO-3107 to Be Featured at the AACR-IO Conference

On February 23-26, 2025, the American Association for Cancer Research (AACR) Immuno-Oncology (IO) Conference will feature significant advancements in the battle against HPV-related diseases, specifically through the research conducted by INOVIO Pharmaceuticals. The biotechnology company, which operates under the NASDAQ ticker INO, will be presenting compelling immune response data related to its novel treatment INO-3107.

What is INO-3107?

INO-3107 is part of INOVIO's broader mission to develop innovative DNA medicines that provide both treatment and protection against various diseases, including cancers associated with the human papillomavirus (HPV). This cutting-edge therapy is designed to instruct the body to produce its own disease-fighting agents, a technique that has shown promising results in preliminary studies.

Conference Presentation Details

The focal point of INOVIO's presentation at the AACR-IO will be an abstract titled "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107." This poster will delve into how INO-3107 has led to the remarkable reduction of HPV-6 in patients suffering from recurrent respiratory papillomatosis, a serious condition caused by viral infection.

Importance of the Findings

The implications of these findings could be transformative for patients impacted by HPV-related ailments. With HPV being a known contributor to several types of cancers, effective immunotherapies like INO-3107 offer hope for improved treatment frameworks. The ability to induce active T cells in patients signifies a leap forward in how the immune system can effectively tackle viral infections and related tumors.

Availability of Research Results

Following the AACR-IO Conference, details from the poster will be made publicly available on INOVIO's official website, providing crucial insights for researchers, healthcare professionals, and the public on this important work in cancer immunology.

About INOVIO Pharmaceuticals

INOVIO is recognized as a pioneer in the biotechnology industry, specializing in the development of DNA medicine to fight against viral infections, cancers, and other diseases. With a strong commitment to utilizing cutting-edge technology, INOVIO designs and optimizes therapies that teach the body to generate its own defense mechanisms against diverse health threats. Their ongoing research endeavors aim to empower patients and expand treatment possibilities through innovative approaches to medicine.

For those interested in the latest advancements in cancer immunology and HPV treatments, the AACR-IO Conference promises to be a significant event, highlighting groundbreaking research and potential new pathways for patient care. For more information on INOVIO and their developments, visit www.inovio.com.